MARKET

ARDS

ARDS

Aridis Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.77
-0.03
-0.52%
Closed 16:00 03/31 EDT
OPEN
5.77
PREV CLOSE
5.81
HIGH
5.77
LOW
5.77
VOLUME
138
TURNOVER
--
52 WEEK HIGH
12.40
52 WEEK LOW
3.800
MARKET CAP
51.42M
P/E (TTM)
-1.6155
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARDS stock price target is 17.80 with a high estimate of 25.00 and a low estimate of 7.00.

EPS

ARDS News

More
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Aridis Pharmaceuticals to Postpone Investor Day Due to Coronavirus Concerns
  • PR Newswire · 03/06 21:05
  • Key events next week - healthcare
  • Seeking Alpha - Article · 03/06 13:09
  • Aridis Pharmaceuticals to Present at the 32nd Annual ROTH Conference
  • PR Newswire · 03/05 10:30

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About ARDS

Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.
More

Webull offers kinds of Aridis Pharmaceuticals Inc stock information, including NASDAQ:ARDS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDS stock news, and many more online research tools to help you make informed decisions.